VEGF-C、VEGFR-3和BMP-9在非小细胞肺癌中的表达及其意义
发布时间：2018-07-28 10:04
【摘要】：目的观察非小细胞肺癌肿瘤组织、癌旁正常肺组织及淋巴结中VEGF-C、VEGFR-3及BMP-9的表达情况,并结合临床病理特征分析其表达在非小细胞肺癌原发病灶进展及淋巴结转移等生物学行为中的意义。方法选择行肺叶切除+淋巴结清扫术、术后我院病理证实的NSCLC患者的组织标本为研究对象,并收集患者的完整病例资料。总共收集到入组患者的51例肿瘤组织、51例对应的癌旁正常肺组织、43枚癌转移淋巴结(其中8例N1期患者:N1期淋巴结15枚;16例N2期患者:N1期淋巴结9枚,N2期淋巴结19枚)及51枚非转移性淋巴结(患侧10组或11组)。采用免疫组织化学法分别检测51例NSCLC癌组织及51例正常肺组织中VEGF-C、VEGFR-3和BMP-9的表达,分别检测43枚癌转移阳性淋巴结及51枚非转移淋巴结中VEGF-C、VEGFR-3的表达。结合阳性细胞百分率和细胞总体染色强度对组织染色结果进行半定量积分分析,计算出对应的阳性表达率,最后经统计发现VEGF-C、VEGFR-3和BMP-9在不同性别、年龄、吸烟史、肿瘤组织类型、肿瘤T分期、淋巴结转移情况、淋巴结N分期及转移淋巴结数目等亚组的阳性表达率,并分析VEGF-C、VEGFR-3和BMP-9的表达在亚组间的统计学关系及内在联系。结果1.VEGF-C阳性表达为棕黄色,主要位于癌细胞胞质内。N0期亚组、N1期亚组、N2期亚组中肿瘤组织VEGF-C表达率均显著高于对应的癌旁正常肺组织(P0.05)。肿瘤组织中VEGF-C的表达在有淋巴结转移组高于无淋巴结转移组,差异有非常显著统计学意义(P0.01)。正常肺组织中VEGF-C的表达在无淋巴结转移组高于有淋巴结转移组,差异有显著统计学意义(P0.05)。癌组织VEGF-C的表达在N2期亚组高于N1期亚组,差异有显著统计学意义(P0.05)。癌组织VEGF-C的表达在N2期亚组高于N0期亚组,差异有显著统计学意义(P0.05)。癌组织VEGF-C的表达在淋巴结转移数目≥3(LN+)亚组高于0(LN+)亚组,差异有非常显著统计学意义(P0.01)。癌组织VEGF-C的表达在淋巴结转移数目≥3(LN+)亚组高于1~2(LN+)亚组,差异有显著统计学意义(P0.05)。正常肺组织VEGF-C的表达在淋巴结转移数目0(LN+)亚组高于≥3(LN+)亚组,差异有显著统计学意义(P0.05)。正常肺组织VEGF-C的表达在淋巴结转移数目1~2(LN+)亚组高于≥3(LN+)亚组,差异有显著统计学意义(P0.05)。在无淋巴结转移的肿瘤组织中,VEGF-C的表达在T3-4期亚组高于T2期亚组,差异有显著统计学意义(P0.05)。在无淋巴结转移的正常肺组织中,VEGF-C的表达在T3-4期亚组高于T2期亚组,差异有显著统计学意义(P0.05)。2.VEGFR-3阳性表达为棕黄色,主要位于淋巴管内皮细胞和部分癌细胞胞浆。N0期亚组、N1期亚组、N2期亚组中肿瘤组织VEGFR-3表达率均显著高于对应的癌旁正常肺组织(P0.05)。肿瘤组织中VEGFR-3的表达在有淋巴结转移组高于无淋巴结转移组,差异有显著统计学意义(P0.05)。正常肺组织中VEGFR-3的表达在有淋巴结转移组高于无淋巴结转移组,差异有显著统计学意义(P0.05)。癌组织VEGFR-3的表达在N2期亚组高于N1期亚组,差异有显著统计学意义(P0.05)。癌组织VEGFR-3的表达在N2期亚组高于N0期亚组,差异有显著统计学意义(P0.05)。正常肺组织VEGFR-3的表达在N2期亚组高于N1期亚组,差异有显著统计学意义(P0.05)。正常肺组织VEGFR-3的表达在N2期亚组高于N0期亚组,差异有显著统计学意义(P0.05)。癌组织VEGFR-3的表达在淋巴结转移数目≥3(LN+)亚组高于0(LN+)亚组,差异有显著统计学意义(P0.05)。正常肺组织VEGFR-3的表达在淋巴结转移数目≥3(LN+)亚组高于0(LN+)亚组,差异有显著统计学意义(P0.05)。在无淋巴结转移的NSCLC正常肺组织中,VEGFR-3的表达在T3-4期亚组高于T1期亚组,差异有显著统计学意义(P0.05)。在无淋巴结转移的NSCLC正常肺组织中,VEGF-C的表达在T3-4期亚组高于T2期亚组,差异有显著统计学意义(P0.05)。3.BMP-9阳性表达为棕黄色,主要位于正常癌旁肺组织细胞及部分癌细胞、巨噬细胞胞质。N0期亚组、N2期亚组的癌旁正常肺组织BMP-9表达显著高于对应的肿瘤组织(P0.05)。N1期亚组的肿瘤组织BMP-9表达显著高于对应的癌旁正常肺组织(P0.05)。肿瘤组织中BMP-9的表达在有淋巴结转移组高于无淋巴结转移组,差异有非常显著统计学意义(P0.01)。正常肺组织中BMP-9的表达在有淋巴结转移组高于无淋巴结转移组,差异有显著统计学意义(P0.05)。癌组织BMP-9的表达在N1期亚组高于N0期亚组,差异有显著统计学意义(P0.01)。癌组织BMP-9的表达在N1期亚组高于N2期亚组,差异有显著统计学意义(P0.05)。癌组织BMP-9的表达在N2期亚组高于N0期亚组,差异有显著统计学意义(P0.05)。正常肺组织BMP-9的表达在N2期亚组高于N1期亚组,差异有显著统计学意义(P0.05)。正常肺组织BMP-9的表达在N2期亚组高于N0期亚组,差异有显著统计学意义(P0.01)。癌组织BMP-9的表达在淋巴结转移数目1~2(LN+)亚组高于0(LN+)亚组,差异有显著统计学意义(P0.05)。癌组织BMP-9的表达在淋巴结转移数目≥3(LN+)亚组高于0(LN+)亚组,差异有显著统计学意义(P0.05)。正常肺组织BMP-9的表达在淋巴结转移数目≥3(LN+)亚组高于0(LN+)亚组,差异有显著统计学意义(P0.05)。在有淋巴结转移的NSCLC肿瘤组织中,BMP-9的表达在T3-4期亚组高于T1期亚组,差异有显著统计学意义(P0.05)。在有淋巴结转移的NSCLC肿瘤组织中,BMP-9的表达在T3-4期亚组高于T2期亚组,差异有显著统计学意义(P0.05)。在有淋巴结转移的NSCLC正常肺组织中,BMP-9的表达在T3-4期亚组高于T1期亚组,差异有显著统计学意义(P0.05)。在有淋巴结转移的NSCLC正常肺组织中,BMP-9的表达在T3-4期亚组高于T2期亚组,差异有显著统计学意义(P0.05)。在无淋巴结转移的NSCLC肿瘤组织中,BMP-9的表达在T3-4期亚组高于T2期亚组,差异有显著统计学意义(P0.05)。4.肿瘤组织及癌旁组织中VEGF-C、VEGFR-3、BMP-9的表达在各个性别、年龄、吸烟史、肿瘤组织类型亚组之间均无显著差异(P0.05)。5.淋巴结VEGF-C的表达在N1期亚组较N0期亚组升高,差异有显著统计学意义(P0.05);淋巴结VEGFR-3的表达在N1期亚组较N0期亚组升高,差异有非常显著统计学意义(P0.01)。淋巴结VEGF-C的表达在N2期亚组较N1期亚组升高,差异有非常显著统计学意义(P0.01);淋巴结VEGFR-3的表达在N2期亚组较N1期亚组升高,差异有显著统计学意义(P0.05)。淋巴结VEGF-C的表达在N2期亚组较N0期亚组升高,差异有非常显著统计学意义(P0.01);淋巴结VEGFR-3的表达在N2期亚组较N0期亚组升高,差异有非常显著统计学意义(P0.01)。6.VEGF-C、VEGFR-3在所有入组的51例NSCLC癌组织中的表达存在明显的正相关(r=0.346,P0.05);VEGF-C、VEGFR-3在有淋巴结转移的24例NSCLC癌组织中的表达存在明显的正相关(r=0.755,P0.01)。VEGF-C、VEGFR-3在所有入组的43例NSCLC转移淋巴结中的表达亦存在明显的正相关(r=0.436,P0.01);VEGF-C、VEGFR-3在23例N1期NSCLC淋巴结中的表达亦存在明显的正相关(r=0.874,P0.01);VEGF-C、VEGFR-3在44例N2期NSCLC淋巴结中的表达亦存在明显的正相关(r=0.702,P0.01)。结论1.VEGF-C、VEGFR-3在不同N分期的NSCLC癌组织中的表达均较癌旁组织明显增高。VEGF-C、VEGFR-3在NSCLC肿瘤组织中的表达均与淋巴结转移有显著的相关性。VEGF-C、VEGFR-3在NSCLC正常肺组织中的表达均与淋巴结转移有显著的相关性。NSCLC癌组织VEGF-C、VEGFR-3的表达在N2期亚组较N1期亚组、N0期亚组均显著升高。NSCLC正常肺组织VEGFR-3的表达在N2期亚组较N1期亚组、N0期亚组均显著升高。癌组织VEGF-C、VEGFR-3的表达在淋巴结转移数目≥3(LN+)亚组较0(LN+)亚组均显著升高。癌组织VEGF-C的表达在淋巴结转移数目≥3(LN+)亚组较1~2(LN+)亚组显著升高。NSCLC正常肺组织VEGF-C、VEGFR-3的表达在淋巴结转移数目≥3(LN+)亚组较0(LN+)亚组均显著升高。NSCLC正常肺组织VEGF-C的表达在淋巴结转移数目≥3(LN+)亚组较1~2(LN+)亚组显著升高。在无淋巴结转移的肿瘤组织及正常肺组织中,VEGF-C在T3-4期亚组的表达显著高于T2期亚组。在无淋巴结转移的NSCLC正常肺组织中,VEGFR-3的表达在T3-4期亚组高于T1期亚组、T2期亚组。VEGF-C、VEGFR-3在有淋巴结转移的肿瘤组织中的表达具有明显正相关性,且两者在转移淋巴结中的表达亦具有明显正相关性。VEGF-C、VEGFR-3在淋巴结中的表达与淋巴结N分期显著相关。我们观察到在NSCLC肿瘤组织及转移淋巴结中VEGF-C、VEGFR-3的表达上调与既往文献报告中其他恶性肿瘤组织的两者表达情况类似,VEGF-C、VEGFR-3可能参与NSCLC原发癌灶局部侵袭、淋巴管生成及淋巴结转移。2.BMP-9在N0期及N2期的NSCLC癌组织中的表达较癌旁组织显著降低,而在N1期癌组织中的表达较癌旁组织显著升高。BMP-9在NSCLC肿瘤组织及正常肺组织中的表达与淋巴结转移均存在显著的相关性。NSCLC肿瘤组织BMP-9的表达在N1期亚组较N0期亚组、N2期亚组显著升高,在N2期亚组较N0期亚组亦显著升高。肿瘤组织BMP-9的表达在淋巴结转移数目≥3(LN+)亚组较0(LN+)亚组显著升高,在淋巴结转移数目为1~2(LN+)亚组较0(LN+)亚组亦显著升高。正常肺组织BMP-9的表达在N2期亚组较N1期亚组、N0期亚组均显著升高。正常肺组织BMP-9的表达在淋巴结转移数目≥3(LN+)亚组较0(LN+)亚组显著升高。在有淋巴结转移的肿瘤组织中,BMP-9在T3-4期亚组的表达显著高于T2期亚组、T1期亚组。在有淋巴结转移的正常肺组织中,BMP-9在T3-4期亚组的表达显著高于T2期亚组、T1期亚组。在无淋巴结转移的肿瘤组织中,BMP-9在T3-4期亚组的表达显著高于T2期亚组。我们观察到在无淋巴结转移的NSCLC肿瘤组织BMP-9的表达相对癌旁组织下降,而在有淋巴结转移的NSCLC肿瘤组织及正常肺组织中BMP-9表达相对升高的现象与既往文献报告中其他恶性肿瘤组织的BMP-9表达情况类似,BMP-9可能与NSCLC原发癌灶局部侵袭、肿瘤淋巴管生成及淋巴结转移相关。3.NSCLC肿瘤组织及癌旁组织中VEGF-C、VEGFR-3、BMP-9的表达均与患者性别、年龄、吸烟史、肿瘤组织类型无相关性。4.VEGF-C、VEGFR-3在NSCLC肿瘤组织、癌旁正常肺组织及淋巴结中的表达与NSCLC淋巴管生成、淋巴结转移具有一定正相关性,而BMP-9在NSCLC肿瘤组织、癌旁组织中的表达与NSCLC淋巴管生成、淋巴结转移具有一定负相关性。以上结论有益于进一步研究NSCLC转移的正负靶向调控治疗。
[Abstract]:Objective To observe the expression of VEGF-C, VEGFR-3 and BMP-9 in the tumor tissue of non-small cell lung cancer, normal lung tissue and lymph nodes adjacent to the carcinoma, and to analyze the significance of its expression in the biological behavior of primary lesion and lymph node metastasis of non-small cell lung cancer combined with clinicopathological features. Methods pulmonary lobectomy plus lymph node dissection was performed. A total of 51 NSCLC patients were collected and collected in our hospital. A total of 51 tumor tissues were collected, 51 normal paracancerous lung tissues and 43 metastatic lymph nodes (8 N1 patients, 15 N1 lymph nodes, 16 N2 patients, 9 lymph nodes in N1 phase, N2 phase drenching). 19 and 51 non metastatic lymph nodes (10 or 11 sides). The expression of VEGF-C, VEGFR-3 and BMP-9 in 51 cases of NSCLC and 51 normal lung tissues were detected by immunohistochemistry. The expression of VEGF-C and VEGFR-3 in 43 positive lymph nodes and 51 non metastatic lymph nodes were detected respectively. The results of tissue staining were semi quantified by rate and cell overall staining intensity, and the positive expression rate was calculated. Finally, VEGF-C, VEGFR-3 and BMP-9 were found in different sex, age, smoking history, tumor tissue type, tumor T staging, lymph node metastasis, lymph node N staging and the number of metastatic lymph nodes. The expression rate of VEGF-C, VEGFR-3 and BMP-9 expressed in the subgroup. Results the positive expression of 1.VEGF-C was brown, mainly located in the.N0 phase subgroup, N1 phase subgroup, and N2 phase subgroup, and the expression of VEGF-C in the N2 phase subgroup was significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of VEGF-C in the lymph node metastasis group was higher than that in the non lymph node metastasis group. The difference was significant (P0.01). The expression of VEGF-C in the normal lung tissue was higher than that in the lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of VEGF-C in the cancer group was higher than the N1 subgroup in the N2 phase subgroup, and the difference was different. There was significant statistical significance (P0.05). The expression of VEGF-C in the carcinoma tissue was higher than that of the N0 subgroup (P0.05) in the N2 phase subgroup (P0.05). The expression of VEGF-C in the carcinoma tissue was higher than the 0 (LN+) subgroup of the lymph node metastases (LN+) subgroup, and the difference was statistically significant (P0.01). The expression of VEGF-C in the carcinoma tissue was in the number of lymph node metastases. The subgroup over 3 (LN+) was higher than that of the 1~2 (LN+) subgroup, the difference was significant (P0.05). The expression of VEGF-C in the normal lung tissue was higher than that of the subgroup of 0 (LN+) of lymph node metastasis (LN+), and the difference was statistically significant (P0.05). The expression of VEGF-C in normal lung tissue was higher than that in the 1~2 (LN+) subgroup of lymph node metastases (LN+) subgroup (LN+)). There was significant statistical significance (P0.05). In the tumor tissue without lymph node metastasis, the expression of VEGF-C in T3-4 phase subgroup was higher than that in T2 subgroup (P0.05). In normal lung tissue without lymph node metastasis, the expression of VEGF-C in T3-4 phase subgroup was higher than that of T2 phase subgroup (P0.05).2.VEGFR-3 (P0.05).2.VEGFR-3. The positive expression was brown yellow, mainly located in the lymphovascular endothelial cells and part of the cytoplasm.N0 subgroup of cancer cells, the N1 phase subgroup and the N2 phase subgroup were significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of VEGFR-3 in the tumor tissue was higher than that in the non lymph node group, and the difference was significantly higher than that in the non lymph node group. Statistical significance (P0.05). The expression of VEGFR-3 in the normal lung tissue was higher than that in the non lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of VEGFR-3 in the carcinoma tissue was higher than that in the N1 subgroup (P0.05). The expression of VEGFR-3 in the cancer tissue was higher than the N0 phase in the N2 subgroup. The difference was significant (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that in phase N1 subgroup (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that of N0 phase subgroup (P0.05) in N2 phase subgroup (P0.05). The expression of VEGFR-3 in cancer tissue was more than 3 (L) in lymph node metastasis (L). N+) the subgroup was higher than the 0 (LN+) subgroup, and the difference was significant (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that of the 0 (LN+) subgroup with the number of lymph node metastasis (LN+), and the difference was statistically significant (P0.05). The expression of VEGFR-3 in the T3-4 phase subgroup was higher than that in the T1 phase group in the normal lung tissue without lymph node metastasis. There was significant statistical significance (P0.05). In the normal lung tissue of NSCLC without lymph node metastasis, the expression of VEGF-C in the T3-4 subgroup was higher than that of the T2 phase subgroup. The difference was statistically significant (P0.05) the positive expression of.3.BMP-9 was brown, mainly located in the normal paracancerous lung tissue cells and some cancer cells, the.N0 phase subgroup of macrophage cytoplasm, and the N2 subgroup The expression of BMP-9 in the normal lung tissue adjacent to the carcinoma was significantly higher than that of the corresponding tumor tissue (P0.05).N1 phase subgroup, and the expression of BMP-9 was significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of BMP-9 in the tumor tissue was higher than that in the non lymph node group (P0.01). The difference was significant (P0.01). The expression of BMP-9 in the lymph node metastasis group was higher than that in the non lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of BMP-9 in the carcinoma tissue was higher than that in the N0 phase group (P0.01). The expression of BMP-9 in the cancer tissue was higher than the N2 group in the N1 phase subgroup, and the difference was significant statistically significant (P0.05). The expression of BMP-9 in the N2 phase was higher than that of the N0 subgroup (P0.05). The expression of BMP-9 in the normal lung tissue was higher than that in the N1 subgroup (P0.05). The expression of BMP-9 in the normal lung tissue was higher than that in the N0 phase group (P0.01). The difference was statistically significant (P0.01). The expression of BMP-9 in the lymph node metastasis number 1~2 (LN+) subgroup was higher than that of the 0 (LN+) subgroup, the difference was significant (P0.05). The expression of BMP-9 in the carcinoma tissue was higher than the 0 (LN+) subgroup of the lymph node metastasis number (LN+) subgroup, and the difference was significant (P0.05). The expression of BMP-9 in normal lung tissue was more than 3 (LN+) subgroup of lymph node metastasis. The difference was significant (P0.05) in the group of 0 (LN+) subgroup (P0.05). In the NSCLC tumor with lymph node metastasis, the expression of BMP-9 was higher than that of the T1 subgroup (P0.05). In NSCLC tumor tissues with lymph node metastasis, the expression of BMP-9 in the T3-4 phase subgroup was higher than that in the T2 phase group, and the difference was significant. P0.05. In NSCLC normal lung tissues with lymph node metastasis, the expression of BMP-9 in the T3-4 subgroup was higher than that in the T1 phase subgroup, and the difference was statistically significant (P0.05). In the normal lung tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 phase group was higher than the T2 phase subgroup, and the difference was statistically significant (P0.05). In the non lymphatic group, the difference was significant (P0.05). In NSCLC tumor metastases, the expression of BMP-9 in T3-4 phase subgroup was higher than that of phase T2 subgroup. The difference was significant (P0.05).4. tumor tissue and the expression of VEGF-C, VEGFR-3, and BMP-9 in.4. tumor tissues and adjacent tissues, and there was no significant difference between the sex, age, smoking history and tumor tissue subgroup (P0.05).5. lymph node VEGF-C. The difference was significant (P0.05) in the group N1 subgroup compared with the N0 subgroup (P0.05); the expression of VEGFR-3 in the lymph node was higher than that in the N0 phase subgroup (P0.01). The expression of VEGF-C in lymph node was higher in the N2 group than in the N1 phase subgroup, and the difference was statistically significant (P0.01); lymph node VEGFR-3. The expression in phase N2 subgroup was higher than that in N1 subgroup (P0.05). The expression of VEGF-C in lymph node was higher than that in N0 phase subgroup, and the difference was statistically significant (P0.01); the expression of VEGFR-3 in lymph node was higher in the N2 phase than in the N0 phase subgroup, and the difference was statistically significant (P0.01).6.VEGF-C. There was a significant positive correlation (r=0.346, P0.05) in the expression of R-3 in all 51 cases of NSCLC cancer, and VEGF-C, VEGFR-3 had a significant positive correlation (r=0.755, P0.01).VEGF-C in 24 cases of NSCLC carcinoma with lymph node metastasis, and VEGFR-3 was also positively correlated with the expression of the 43 cases of NSCLC metastatic lymph nodes. =0.436, P0.01); VEGF-C, VEGFR-3 was also positively correlated (r=0.874, P0.01) in 23 N1 phase NSCLC lymph nodes. VEGF-C, VEGFR-3 was also positively correlated in the 44 N2 NSCLC lymph nodes. The expression of VEGFR-3 in NSCLC tumor tissues was significantly correlated with lymph node metastasis, and the expression of VEGFR-3 in NSCLC normal lung tissues was significantly correlated with lymph node metastasis of.NSCLC cancer tissue VEGF-C, VEGFR-3 expression in the N2 phase subgroup was higher than that in the N1 phase group, and the N0 phase subgroup significantly increased the normal lung group. The expression of VEGFR-3 was significantly higher in the N2 subgroup than in the N1 phase subgroup and in the N0 phase subgroup. The expression of VEGF-C and VEGFR-3 in the carcinoma tissue was significantly higher in the number of lymph node metastases (LN+) than in the 0 (LN+) subgroup. The expression of VEGF-C in the carcinoma tissue was significantly higher in the number of lymph node metastases (LN+) than in the 1~2 (LN+) subgroup. The expression of GFR-3 in the group of lymph node metastasis more than 3 (LN+) was significantly higher than that of the 0 (LN+) subgroup. The expression of VEGF-C in the normal lung tissue of.NSCLC was significantly higher than that in the subgroup of 1~2 (LN+) with the number of lymph node metastases more than 3 (LN+). In the tumor tissue without lymph node metastasis and in the normal lung group, the expression of VEGF-C in the T3-4 phase subgroup was significantly higher than that of the T2 phase subgroup. In NSCLC normal lung tissues without lymph node metastasis, the expression of VEGFR-3 in the T3-4 phase subgroup was higher than that in the T1 subgroup. The T2 phase subgroup.VEGF-C, VEGFR-3 had a positive correlation in the tumor tissue with lymph node metastasis, and the expression of the two in the metastatic lymph nodes also had a significant positive correlation of.VEGF-C and VEGFR-3 in the lymph nodes. The expression of VEGF-C was significantly correlated with the N staging of lymph nodes. We observed that the expression of VEGF-C in NSCLC tumor tissues and metastatic lymph nodes was similar to those of other malignant tumor tissues in previous reports. VEGF-C, VEGFR-3 may be involved in the local invasion, lymphangiogenesis and lymph node metastasis of the primary cancer of the NSCLC. The expression of NSCLC in the N0 and N2 phase was significantly lower than that in the paracancerous tissue, while the expression in the N1 carcinoma tissue was significantly higher than that of the paracancerous tissue. The expression of.BMP-9 in the NSCLC tumor tissue and the normal lung tissue was significantly correlated with the lymph node metastasis. The expression of BMP-9 in the.NSCLC tumor tissue was compared with the N0 phase subgroup in the N1 phase group and the N2 phase. The subgroup was significantly higher in the subgroup N2 than the N0 subgroup. The expression of BMP-9 in the tumor tissue was significantly higher than the 0 (LN+) subgroup with the number of lymph node metastases (LN+), and the number of lymph node metastasis was 1~2 (LN+) subgroup as compared with the 0 (LN+) subgroup. The expression of BMP-9 in the normal lung tissue was in the N2 phase subgroup than the N1 subgroup and the N0 phase subgroup The expression of BMP-9 in normal lung tissue was significantly higher in the subgroup of lymph node metastasis (LN+) than in the subgroup of 0 (LN+). In the tumor tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 phase subgroup was significantly higher than that of the T2 phase subgroup and the T1 phase subgroup. In the normal lung tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 subgroup was significant. The expression of BMP-9 in the T3-4 phase subgroup was significantly higher than that in the T2 phase subgroup in the non lymph node metastases. We observed that the expression of BMP-9 in the NSCLC tumor tissue without lymph node metastasis was lower than that of the para cancerous tissue in the NSCLC tumor tissue without lymph node metastasis, and the BMP-9 expression in the NSCLC tumor tissue and normal lung tissues with lymph node metastasis was observed. Similar to the BMP-9 expression in other malignant tumor tissues reported previously, BMP-9 may be associated with NSCLC primary cancer site.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2
本文编号：2149736
[Abstract]:Objective To observe the expression of VEGF-C, VEGFR-3 and BMP-9 in the tumor tissue of non-small cell lung cancer, normal lung tissue and lymph nodes adjacent to the carcinoma, and to analyze the significance of its expression in the biological behavior of primary lesion and lymph node metastasis of non-small cell lung cancer combined with clinicopathological features. Methods pulmonary lobectomy plus lymph node dissection was performed. A total of 51 NSCLC patients were collected and collected in our hospital. A total of 51 tumor tissues were collected, 51 normal paracancerous lung tissues and 43 metastatic lymph nodes (8 N1 patients, 15 N1 lymph nodes, 16 N2 patients, 9 lymph nodes in N1 phase, N2 phase drenching). 19 and 51 non metastatic lymph nodes (10 or 11 sides). The expression of VEGF-C, VEGFR-3 and BMP-9 in 51 cases of NSCLC and 51 normal lung tissues were detected by immunohistochemistry. The expression of VEGF-C and VEGFR-3 in 43 positive lymph nodes and 51 non metastatic lymph nodes were detected respectively. The results of tissue staining were semi quantified by rate and cell overall staining intensity, and the positive expression rate was calculated. Finally, VEGF-C, VEGFR-3 and BMP-9 were found in different sex, age, smoking history, tumor tissue type, tumor T staging, lymph node metastasis, lymph node N staging and the number of metastatic lymph nodes. The expression rate of VEGF-C, VEGFR-3 and BMP-9 expressed in the subgroup. Results the positive expression of 1.VEGF-C was brown, mainly located in the.N0 phase subgroup, N1 phase subgroup, and N2 phase subgroup, and the expression of VEGF-C in the N2 phase subgroup was significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of VEGF-C in the lymph node metastasis group was higher than that in the non lymph node metastasis group. The difference was significant (P0.01). The expression of VEGF-C in the normal lung tissue was higher than that in the lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of VEGF-C in the cancer group was higher than the N1 subgroup in the N2 phase subgroup, and the difference was different. There was significant statistical significance (P0.05). The expression of VEGF-C in the carcinoma tissue was higher than that of the N0 subgroup (P0.05) in the N2 phase subgroup (P0.05). The expression of VEGF-C in the carcinoma tissue was higher than the 0 (LN+) subgroup of the lymph node metastases (LN+) subgroup, and the difference was statistically significant (P0.01). The expression of VEGF-C in the carcinoma tissue was in the number of lymph node metastases. The subgroup over 3 (LN+) was higher than that of the 1~2 (LN+) subgroup, the difference was significant (P0.05). The expression of VEGF-C in the normal lung tissue was higher than that of the subgroup of 0 (LN+) of lymph node metastasis (LN+), and the difference was statistically significant (P0.05). The expression of VEGF-C in normal lung tissue was higher than that in the 1~2 (LN+) subgroup of lymph node metastases (LN+) subgroup (LN+)). There was significant statistical significance (P0.05). In the tumor tissue without lymph node metastasis, the expression of VEGF-C in T3-4 phase subgroup was higher than that in T2 subgroup (P0.05). In normal lung tissue without lymph node metastasis, the expression of VEGF-C in T3-4 phase subgroup was higher than that of T2 phase subgroup (P0.05).2.VEGFR-3 (P0.05).2.VEGFR-3. The positive expression was brown yellow, mainly located in the lymphovascular endothelial cells and part of the cytoplasm.N0 subgroup of cancer cells, the N1 phase subgroup and the N2 phase subgroup were significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of VEGFR-3 in the tumor tissue was higher than that in the non lymph node group, and the difference was significantly higher than that in the non lymph node group. Statistical significance (P0.05). The expression of VEGFR-3 in the normal lung tissue was higher than that in the non lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of VEGFR-3 in the carcinoma tissue was higher than that in the N1 subgroup (P0.05). The expression of VEGFR-3 in the cancer tissue was higher than the N0 phase in the N2 subgroup. The difference was significant (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that in phase N1 subgroup (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that of N0 phase subgroup (P0.05) in N2 phase subgroup (P0.05). The expression of VEGFR-3 in cancer tissue was more than 3 (L) in lymph node metastasis (L). N+) the subgroup was higher than the 0 (LN+) subgroup, and the difference was significant (P0.05). The expression of VEGFR-3 in normal lung tissue was higher than that of the 0 (LN+) subgroup with the number of lymph node metastasis (LN+), and the difference was statistically significant (P0.05). The expression of VEGFR-3 in the T3-4 phase subgroup was higher than that in the T1 phase group in the normal lung tissue without lymph node metastasis. There was significant statistical significance (P0.05). In the normal lung tissue of NSCLC without lymph node metastasis, the expression of VEGF-C in the T3-4 subgroup was higher than that of the T2 phase subgroup. The difference was statistically significant (P0.05) the positive expression of.3.BMP-9 was brown, mainly located in the normal paracancerous lung tissue cells and some cancer cells, the.N0 phase subgroup of macrophage cytoplasm, and the N2 subgroup The expression of BMP-9 in the normal lung tissue adjacent to the carcinoma was significantly higher than that of the corresponding tumor tissue (P0.05).N1 phase subgroup, and the expression of BMP-9 was significantly higher than that of the corresponding normal lung tissue (P0.05). The expression of BMP-9 in the tumor tissue was higher than that in the non lymph node group (P0.01). The difference was significant (P0.01). The expression of BMP-9 in the lymph node metastasis group was higher than that in the non lymph node metastasis group, and the difference was statistically significant (P0.05). The expression of BMP-9 in the carcinoma tissue was higher than that in the N0 phase group (P0.01). The expression of BMP-9 in the cancer tissue was higher than the N2 group in the N1 phase subgroup, and the difference was significant statistically significant (P0.05). The expression of BMP-9 in the N2 phase was higher than that of the N0 subgroup (P0.05). The expression of BMP-9 in the normal lung tissue was higher than that in the N1 subgroup (P0.05). The expression of BMP-9 in the normal lung tissue was higher than that in the N0 phase group (P0.01). The difference was statistically significant (P0.01). The expression of BMP-9 in the lymph node metastasis number 1~2 (LN+) subgroup was higher than that of the 0 (LN+) subgroup, the difference was significant (P0.05). The expression of BMP-9 in the carcinoma tissue was higher than the 0 (LN+) subgroup of the lymph node metastasis number (LN+) subgroup, and the difference was significant (P0.05). The expression of BMP-9 in normal lung tissue was more than 3 (LN+) subgroup of lymph node metastasis. The difference was significant (P0.05) in the group of 0 (LN+) subgroup (P0.05). In the NSCLC tumor with lymph node metastasis, the expression of BMP-9 was higher than that of the T1 subgroup (P0.05). In NSCLC tumor tissues with lymph node metastasis, the expression of BMP-9 in the T3-4 phase subgroup was higher than that in the T2 phase group, and the difference was significant. P0.05. In NSCLC normal lung tissues with lymph node metastasis, the expression of BMP-9 in the T3-4 subgroup was higher than that in the T1 phase subgroup, and the difference was statistically significant (P0.05). In the normal lung tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 phase group was higher than the T2 phase subgroup, and the difference was statistically significant (P0.05). In the non lymphatic group, the difference was significant (P0.05). In NSCLC tumor metastases, the expression of BMP-9 in T3-4 phase subgroup was higher than that of phase T2 subgroup. The difference was significant (P0.05).4. tumor tissue and the expression of VEGF-C, VEGFR-3, and BMP-9 in.4. tumor tissues and adjacent tissues, and there was no significant difference between the sex, age, smoking history and tumor tissue subgroup (P0.05).5. lymph node VEGF-C. The difference was significant (P0.05) in the group N1 subgroup compared with the N0 subgroup (P0.05); the expression of VEGFR-3 in the lymph node was higher than that in the N0 phase subgroup (P0.01). The expression of VEGF-C in lymph node was higher in the N2 group than in the N1 phase subgroup, and the difference was statistically significant (P0.01); lymph node VEGFR-3. The expression in phase N2 subgroup was higher than that in N1 subgroup (P0.05). The expression of VEGF-C in lymph node was higher than that in N0 phase subgroup, and the difference was statistically significant (P0.01); the expression of VEGFR-3 in lymph node was higher in the N2 phase than in the N0 phase subgroup, and the difference was statistically significant (P0.01).6.VEGF-C. There was a significant positive correlation (r=0.346, P0.05) in the expression of R-3 in all 51 cases of NSCLC cancer, and VEGF-C, VEGFR-3 had a significant positive correlation (r=0.755, P0.01).VEGF-C in 24 cases of NSCLC carcinoma with lymph node metastasis, and VEGFR-3 was also positively correlated with the expression of the 43 cases of NSCLC metastatic lymph nodes. =0.436, P0.01); VEGF-C, VEGFR-3 was also positively correlated (r=0.874, P0.01) in 23 N1 phase NSCLC lymph nodes. VEGF-C, VEGFR-3 was also positively correlated in the 44 N2 NSCLC lymph nodes. The expression of VEGFR-3 in NSCLC tumor tissues was significantly correlated with lymph node metastasis, and the expression of VEGFR-3 in NSCLC normal lung tissues was significantly correlated with lymph node metastasis of.NSCLC cancer tissue VEGF-C, VEGFR-3 expression in the N2 phase subgroup was higher than that in the N1 phase group, and the N0 phase subgroup significantly increased the normal lung group. The expression of VEGFR-3 was significantly higher in the N2 subgroup than in the N1 phase subgroup and in the N0 phase subgroup. The expression of VEGF-C and VEGFR-3 in the carcinoma tissue was significantly higher in the number of lymph node metastases (LN+) than in the 0 (LN+) subgroup. The expression of VEGF-C in the carcinoma tissue was significantly higher in the number of lymph node metastases (LN+) than in the 1~2 (LN+) subgroup. The expression of GFR-3 in the group of lymph node metastasis more than 3 (LN+) was significantly higher than that of the 0 (LN+) subgroup. The expression of VEGF-C in the normal lung tissue of.NSCLC was significantly higher than that in the subgroup of 1~2 (LN+) with the number of lymph node metastases more than 3 (LN+). In the tumor tissue without lymph node metastasis and in the normal lung group, the expression of VEGF-C in the T3-4 phase subgroup was significantly higher than that of the T2 phase subgroup. In NSCLC normal lung tissues without lymph node metastasis, the expression of VEGFR-3 in the T3-4 phase subgroup was higher than that in the T1 subgroup. The T2 phase subgroup.VEGF-C, VEGFR-3 had a positive correlation in the tumor tissue with lymph node metastasis, and the expression of the two in the metastatic lymph nodes also had a significant positive correlation of.VEGF-C and VEGFR-3 in the lymph nodes. The expression of VEGF-C was significantly correlated with the N staging of lymph nodes. We observed that the expression of VEGF-C in NSCLC tumor tissues and metastatic lymph nodes was similar to those of other malignant tumor tissues in previous reports. VEGF-C, VEGFR-3 may be involved in the local invasion, lymphangiogenesis and lymph node metastasis of the primary cancer of the NSCLC. The expression of NSCLC in the N0 and N2 phase was significantly lower than that in the paracancerous tissue, while the expression in the N1 carcinoma tissue was significantly higher than that of the paracancerous tissue. The expression of.BMP-9 in the NSCLC tumor tissue and the normal lung tissue was significantly correlated with the lymph node metastasis. The expression of BMP-9 in the.NSCLC tumor tissue was compared with the N0 phase subgroup in the N1 phase group and the N2 phase. The subgroup was significantly higher in the subgroup N2 than the N0 subgroup. The expression of BMP-9 in the tumor tissue was significantly higher than the 0 (LN+) subgroup with the number of lymph node metastases (LN+), and the number of lymph node metastasis was 1~2 (LN+) subgroup as compared with the 0 (LN+) subgroup. The expression of BMP-9 in the normal lung tissue was in the N2 phase subgroup than the N1 subgroup and the N0 phase subgroup The expression of BMP-9 in normal lung tissue was significantly higher in the subgroup of lymph node metastasis (LN+) than in the subgroup of 0 (LN+). In the tumor tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 phase subgroup was significantly higher than that of the T2 phase subgroup and the T1 phase subgroup. In the normal lung tissue with lymph node metastasis, the expression of BMP-9 in the T3-4 subgroup was significant. The expression of BMP-9 in the T3-4 phase subgroup was significantly higher than that in the T2 phase subgroup in the non lymph node metastases. We observed that the expression of BMP-9 in the NSCLC tumor tissue without lymph node metastasis was lower than that of the para cancerous tissue in the NSCLC tumor tissue without lymph node metastasis, and the BMP-9 expression in the NSCLC tumor tissue and normal lung tissues with lymph node metastasis was observed. Similar to the BMP-9 expression in other malignant tumor tissues reported previously, BMP-9 may be associated with NSCLC primary cancer site.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R734.2
【参考文献】
相关期刊论文 前6条
1 李少雷;陈晋峰;郑庆锋;吴楠;阎石;王洋;张建芝;杨跃;;Endostatin VEGF-C和VEGFR-3在非小细胞肺癌及其淋巴结组织中的表达与意义[J];中国肿瘤临床;2011年24期
2 ;Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma[J];World Journal of Gastroenterology;2006年28期
3 曹桂明;杨梅;;VEGF-C和VEGFR-3对乳腺癌淋巴管生成和淋巴结转移的影响[J];中国肿瘤临床;2006年06期
4 李凯;陶京;王春友;;胰腺癌淋巴管生成与血管内皮生长因子C的关系[J];中华实验外科杂志;2006年01期
5 姜汉国,高嵋,唐慰萍,李飞虹,蔡琼珍;VEGF、VEGF-C和VEGF-D在甲状腺乳头状癌组织中的表达及意义[J];癌症;2005年09期
6 许良中，，杨文涛;免疫组织化学反应结果的判断标准[J];中国癌症杂志;1996年04期
本文编号：2149736
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2149736.html
